Targeting an elevated FVIII level using personalized rurioctocog alfa pegol prophylaxis in specific patient populations with hemophilia A: post hoc subanalysis of the randomized, phase 3 PROPEL study

BACKGROUND: The phase 3, prospective PROPEL study demonstrated that pharmacokinetic (PK)-guided prophylaxis targeting elevated factor VIII (FVIII) troughs in patients with hemophilia A resulted in lower annualized bleeding rates (ABRs) and a higher proportion of patients experiencing zero bleeds in...

Descripción completa

Detalles Bibliográficos
Autores principales: Escuriola-Ettingshausen, Carmen, Klamroth, Robert, Escobar, Miguel, Stasyshyn, Oleksandra, Tangada, Srilatha, Engl, Werner, Honauer, Ivan, Lee, Hye-Youn, Chowdary, Pratima, Windyga, Jerzy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10350756/
https://www.ncbi.nlm.nih.gov/pubmed/37465396
http://dx.doi.org/10.1177/20406207231178596

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10350756/
https://www.ncbi.nlm.nih.gov/pubmed/37465396
http://dx.doi.org/10.1177/20406207231178596

Ejemplares similares